Special issue of Future Medicinal Chemistry explores immunotherapy edit article

August 18, 2017

The field of immunotherapy is moving forward at an unprecedented rate, and a range of therapeutic approaches are now used in clinical practice, often with outstanding success. Cancer immunotherapy, in particular, has recently come of age, with many of the breakthrough drugs showing significant advantages over conventional therapies. In this exciting time, we are delighted to come together with medicinal chemists from around the globe to deliver this timely issue.

The Special Focus issue has been guest edited by Antonio Macchiarulo (University of Perugia, Italy) who provided a scene-setting Foreword, and commented "How can immunotherapy be exploited to provide novel treatments for cancer and autoimmune diseases? This special issue addresses this question from different perspectives, providing the reader with an outlook on recent scientific advances and challenges that have to be tackled in a pursuit race to tomorrow's medicines."

The Special Focus issue contains a variety of content including editorial, review and research articles looking at the challenges faced in immunotherapy drug development. The issue covers the discovery and development of novel immunotherapeutic agents for use as anti-inflammatories and cancer treatments.

"I am delighted to have worked with experts in the field to produce this timely and comprehensive Special Focus Issue discussing the challenges, advancements and novel therapeutic strategies in immunotherapy," stated Rachel Coleby, Commissioning Editor of Future Medicinal Chemistry.

To read the Special Focus Issue on Immunotherapy, please click here -http://www.future-science.com/toc/fmc/9/12
-end-
About Future Medicinal Chemistry

Future Medicinal Chemistry provides monthly commentary and debate on the rapidly evolving field of medicinal chemistry. The MEDLINE-indexed journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research - from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents. Join the Future Medicinal Chemistry Twitter and Linkedin groups for updates.

About MedChemNet

Launched in Spring 2015, MedChemNet is among a suite of online networks from Future Science Group focusing on a range of aspects in medicinal and scientific discovery and enterprise. MedChemNet, is free to join and provides a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships. Ultimately, we hope this dynamic network will provide a catalyst to accelerate progress and encourage collaboration in this ever changing field. http://www.medchemnet.com

Join MedChemNet and help us to connect the dots. Sign up here: https://www.medchemnet.com/users/sign_up

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Nanomedicine and the award-winning Regenerative Medicine. http://www.futuresciencegroup.com. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com.

Future Science Group

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.